The Emergence of a New Conceptual Framework for Alzheimer’s Disease

Bruno Dubois*

Centre des Maladies Cognitives et Comportementales (IM2A), Institut du Cerveau et de la Moelle épinière (ICM), UMR-S975, AP-HP, Salpêtrière Hospital, Pierre et Marie Curie University, Paris, France

Accepted 17 August 2017

Abstract. The New Criteria for the diagnosis of Alzheimer’s disease (AD), published by a group of experts in 2007, have resulted in a revolution in the comprehension of the disease. Before 2007, the diagnosis of AD dementia was done through a process of exclusion: it was considered in the case of patients with a dementia syndrome without identified etiologies. This traditional algorithm had three major limitations that penalize the disease: 1) a low accuracy of the performance which may share responsibility for negative results in clinical trials; 2) a late identification of the patients only when they reach the threshold of dementia which may delay the activation of optimal care; and last but not least, 3) an absence of clear recognition of AD as a disease because of the lack of specific arguments for its identification. Since 2007, the disease has gained a clear definition based on positive evidence: a specific clinical phenotype (the amnestic syndrome of the hippocampal type) and the presence of biomarkers, considered as a biological signature of the disease. Thanks to these positive arguments, AD is a clinically and biologically well-delineated disease, no longer defined as “probable”. It is now possible to certify that a given patient has or does not have the disease. Like diabetes, cancer, hyperthyroidism or any other disorder, AD has now a clear definition with well-defined borders. The disease has entered the world of medicine with identified diseases with a biological fingerprint. This is the story of this adventure that we will present now.

Keywords: Alzheimer’s disease, biomarkers, criteria, diagnosis, preclinical stage, prodromal stage

INTRODUCTION

Based on the classical diagnostic criteria proposed by the National Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders Association (NINCDS-ADRDA) in 1984, the clinical diagnosis of Alzheimer’s disease (AD) was initially considered within a 2-step procedure with an initial identification of a dementia syndrome and then the exclusion of other possible etiologies of dementia with blood/cerebrospinal fluid (CSF) investigations to rule out infectious, inflammatory, or metabolic diseases and with brain neuroimaging [computed tomography (CT) scan or magnetic resonance imaging (MRI)] for excluding small vessel diseases, strategic lacunar infarcts, large vessel infarcts and/or cerebral hemorrhages, brains tumors, hydrocephalus, etc. This was mainly an exclusionary process. Based on these criteria, the clinical diagnosis of AD could not be certified (“probable” AD) and a definite diagnosis needed a histological confirmation based on cerebral biopsy or postmortem examination [1].

In this context, the emergence of a new conceptual framework for AD was progressive and relied on different successive steps that are presented in a chronological fashion.
DISENTANGLING THE MEMORY PROFILES OF DEGENERATIVE DISORDERS

Having worked for years on the cognitive and behavioral changes associated with neurodegenerative disorders involving primarily subcortical structures and basal ganglia (Parkinson’s disease, progressive supranuclear palsy, or Huntington disease), we have conceptualized that these disorders are mainly characterized by a severe executive dysfunction [2]. The frontal dysfunction has a significant impact in various domains in these patients: increased apathy, slowing of central processing time, decreased fluency, lack of flexibility, difficulties in conceptualization and problems solving ability, and memory deficits [3]. Long-term memory is apparently affected in subcortico-frontal dementias as shown by the low performance in word-list recall [4]. However, when encoding of information is controlled in the initial stage of memory processing using semantic category cues and when recall is facilitated with the same cues as with tests such as the Free and Cued Selective Reminding Test (FCSRT) [5], patients’ recall performance is dramatically improved. The preserved ability to retrieve all the items indicates that there was no genuine amnesia in these diseases [4].

This subcortico-frontal pattern of memory deficit is strikingly different from that of patients with AD. In AD, recall performance is not normalized by cueing, indicating the presence of a storage deficit. This finding led us to propose a functional “medio-temporal versus frontal dissociation” to explain the different patterns of memory disorders observed in neurodegenerative diseases [3]. The frontal lobe component mediates the internally generated strategy to guide memory search, which explains the low performance in free recall in patients with frontal lobe dysfunctions. By contrast, the medial temporal/hippocampal component is predominantly impaired in AD and is responsible for encoding deficits, loss of information after delay, low effect of cueing on recall, and high number of extra-list intrusion and false positives in recognition. Therefore, based on these initial studies, we postulated that it is possible to isolate a specific pattern of memory profile that is related to hippocampal damage [6]. In line with this hypothesis, we found that a decrease in the total recall score (the sum of free and cued recall) and in the index of sensitivity to semantic cueing (the percentage of cues that activate the retrieval of correct items that were not spontaneously recalled) were significantly related to AD and that both are good markers of the disease [7].

To summarize, if a poor free recall is the rule in any type of brain damage with memory disorders, a low performance in total recall despite retrieval facilitation is a marker of medio temporal/hippocampal dysfunction and therefore of AD. This “amnestic syndrome of the hippocampal type” successfully differentiates patients with AD from any other memory disorders that are seen in depression, frontal lobe dysfunction, subcortical dementias, or vascular dementias where a low free recall performance is generally normalized (or quasi normalized) by cueing [8].

AD IS A RATHER HOMOGENEOUS DISEASE WITH A STARTING POINT IN MEDIAL TEMPORAL LOBE STRUCTURES

In parallel, the diagnosis accuracy of AD improved significantly in the last decades because of the characterization of new dementias through specific criteria, including the primary progressive aphasias [9], semantic dementia [10], cortico-basal degeneration [11], posterior-cortical atrophy [12], and Lewy body dementia [13].

The individualization of these new diseases, which were previously confused with AD, has consequently decreased its apparent heterogeneity. At the same time, postmortem studies of AD patients provide evidence of a rather specific pattern of cerebral neuronal lesions, which appear to begin within the medial temporal lobe structures (entorhinal cortex, hippocampal formations, para-hippocampal gyrus) [14], structures known to be critical for long-term episodic memory. According to the Braak stages, the initial media-temporal lobe involvement is followed by a progressive diffusion of neuronal lesions to the neocortical areas [15].

AD IS A PROGRESSIVE AMNESTIC DEMENTIA

According to this model, we have proposed that episodic memory deficit is an early and reliable neuropsychological marker of AD [8]. In a follow-up study of 251 patients with mild cognitive impairment (MCI), an amnestic syndrome of the hippocampal type evidenced by the FCSRT, was already present and severe. Moreover, it was by far the best predictor for a further progression to AD dementia within the
next 3 years among all the standardized neuropsychological battery—which included in addition the Benton visual retention test for visual memory, the Deno 100 and verbal fluency for language, the serial digit ordering test and the double task of Badley for working memory, the similarities of the Wechsler Adult Intelligence Scale (WAIS) for conceptual elaboration, the Stroop task, the Trail Making Test, and the WAIS digit symbol test for executive functions [16]. This pattern was also shown to correlate with hippocampal atrophy [17] and grey matter loss of the medial temporal lobe [18]. In addition, it predicts with high accuracy the presence of AD pathology determined in vivo by CSF changes [18, 19] even at a prodromal stage of the disease [20]. Based on these evidence, we proposed AD as characterized by a rather homogeneous clinical presentation, which can be divided into two mains stages: 1) the first stage consists of a progressive and rather isolated amnestic syndrome in relation in the early involvement of the medio-temporal structures; 2) the second is characterized by the addition and the development of cognitive symptoms in the domain of executive (conceptualization, judgment, problem solving) and instrumental (language, praxis, face or object recognition) functions and of psycho-behavioral changes, due to the progressive invading of neocortical areas with neuronal lesions.

IDENTIFICATION OF A PRODROMAL STAGE OF AD

AD pathology is well advanced by the time patients present with their first cognitive symptoms, even though they may not meet current criteria for dementia. Considering AD only at a dementia stage is detrimental to care for patients affected by the disease. There is no reason to link the diagnosis of a disease with a certain threshold of severity and to exclude a large number of patients who are not yet expressing a full-blown dementia from diagnosis and treatment. Early intervention for drug development may be important for effective treatment and there is no justification to anchor the diagnosis of AD to a dementia syndrome. For these reasons, we had already considered in 2000 that the “concept of prodromal AD was more useful than MCI” [21]. MCI is a heterogeneous condition with various underlying etiologies. For the clinician and for the patient, the problem is not diagnosing the syndrome (MCI) but rather detecting the underlying disease (prodromal AD) responsible for the syndrome. The presence of the specific memory pattern, the amnestic of the hippocampal type, even at a predementia stage of the disease, makes it possible to identify, or at least to suspect, AD at a prodromal stage. However, affirming the diagnosis at this stage might be difficult and the consequence of a false diagnosis is very serious. In this context, the discovery of biomarkers of the disease was very timely.

THE ADDED VALUE OF BIOMARKERS

The clinical diagnosis, suggested by a specific phenotype (pattern of memory disorders either isolated or associated with cognitive/behavioral changes), can now be confirmed by the presence of positive biomarkers. For the last decades since the NINCDS-ADRDA criteria were published, great progress has been made with the identification of the AD-associated structural molecular brain changes and their biochemical footprints. MRI enables the measure of medial temporal lobe structures [22]. Positron emission tomography (PET) with fluorodeoxyglucose (FDG) may evidence a temporo-parietal hypometabolism associated with AD even in the early stages [23]. Analysis for CSF can detect the key molecular pathological features of AD [24] as well as PET with amyloid ligands [25], even the prodromal stage of the disease. The availability of specific biomarkers of AD pathology in vivo supports a major change in the conceptualization and diagnosis of the disease, moving the definition of AD from a clinico-pathological entity to a clinico-biological entity. As biomarkers can be considered as surrogate markers of the histopathological changes, the clinical diagnosis can now be established in vivo at any stage of the disease. Reference to dementia may no longer be needed for diagnosing AD. AD should be now considered as a continuum, and it was timely to propose a new set that applies at any stage of the disease.

REVISING THE NINCDS-ADRDA CRITERIA

Considering these advances in clinical phenotype and biomarkers of the disease, providing positive evidence for the diagnosis, we convened with Philip Scheltens and Howard Feldman a working group with 15 international dementia experts in Firenze in 2005 to develop a diagnostic framework for AD that would
The new diagnostic approach

Before 2007: Diagnosis based on an exclusionary process
- dementia: loss of autonomy
- elimination of other causes of dementia:
  □ blood exams: endocrinopathies, infectious or inflammatory disorders
  □ CT-Scan/MRI: vascular lesions, tumor, hydrocephalus

Since 2007: Diagnosis based on positive arguments
- an amnestic syndrome of the hippocampal type
- integration of biomarkers in the diagnostic process:
  □ a biological signature on CSF
  □ the visualization of brain lesions with PET amyloid tracer

include the prodromal stages and the integration of biomarkers and to define the future goals and steps for the validation of such a framework. The workshop was at the origin of a 2007 Lancet Neurology paper [26] on the new research criteria for typical AD. These new criteria proposed that AD can now be defined in vivo with a diagnostic algorithm that is centered on a clinical core of early and significant episodic memory impairment and then requires supporting biomarkers among structural neuroimaging with MRI, molecular neuroimaging with PET, and CSF analysis of amyloid-β (Aβ) or tau proteins (see Table 1). AD is now a clinico-biological entity, which can be identified in vivo and encompasses the whole spectrum of its clinical course. At the time where we published the New Criteria, the respective contribution and the weight of each of biomarker in terms of diagnosis accuracy was not known and this is the reason for the subsequent articles that we published on this matter.

THE NEW LEXICON FOR AD

The new conceptual framework of AD suggests redefining a common lexicon concerning AD and related entities [27].

Alzheimer’s disease

AD now refers to the whole spectrum of the clinical phase of the disease and is not restricted to the dementia syndrome. The diagnosis requires the evidence of an amnestic syndrome of the hippocampal type (defined by a free recall deficit that is not normalized by cueing) and the presence of pathophysiological markers of AD. Distinguishing two different stages may still be meaningful: a prodromal and a dementia phase. However, the transition between the two states may be arbitrary because the underlying disease is a continuous process. Individual clinician’s experience will impact significantly on the threshold of detection of the transition to AD.

AD dementia

This term refers to the phase of AD during which cognitive symptoms are sufficiently severe to interfere with social functioning and instrumental activities of daily living, a threshold that is considered to define dementia in association with changes in episodic memory and in at least one other cognitive domain.

Prodromal AD

This refers to the early symptomatic, predementia phase of the disease, characterized by a specific clinical phenotype of the amnestic syndrome of the hippocampal type with positive pathophysiological biomarkers. The memory disorders can be isolated or associated with other cognitive or behavioral changes that are not severe enough to interfere significantly with activities of daily living. The term of prodromal AD might disappear in the future if AD is considered to encompass both the predementia and dementia stages.

Typical AD

This term refers to the most common clinical phenotype of AD (more than 85% of the cases), characterized by an early significant and progressive episodic memory deficit that remains dominant in the later stages of the disease, and is followed by or associated with other cognitive impairments (executive dysfunction, language, praxis, and complex visual processing impairments) and neuropsychiatric changes. The diagnosis is further supported by one or more in-vivo positive biomarkers of AD pathology.

Atypical AD

This term refers to the less common clinical phenotypes that may occur with AD pathology: logopenic aphasia, posterior cortical atrophy, and frontal variant of AD. In the presence of one of these clinical presentations, the diagnosis of AD is supported by in vivo evidence of pathophysiological biomarkers of AD.
Mixed AD

This term refers to patients who fulfill the diagnostic criteria for typical AD and additionally present with clinical and brain imaging/biological evidence of other comorbid disorders such as cerebrovascular disease or Lewy body disease.

Preclinical AD

This term refers to the long asymptomatic stage between the earliest pathogenic events/brain lesions of AD and the first appearance of specific cognitive changes. Two preclinical states can be isolated in vivo:

Asymptomatic at-risk for AD: Cognitively normal individuals with biomarker evidence of AD pathology. In the absence of knowledge about the value of these biological changes to predict the further development of the disease, they should be referred to as an “at-risk for AD”.

Presymptomatic AD: Cognitively normal individuals sharing an autosomal dominant monogenic AD mutation. Because of the full penetrance of the mutations, they will develop a clinical AD if they live long enough.

Biomarkers of AD

The International Working Group (IWG) has proposed to divide biomarkers into pathophysiological and topographical markers [27] (see Table 2).

Pathophysiological markers identify AD pathology. They target the two etiological degenerative processes that characterize AD pathology: amyloidosis and tauopathy. They are markers of diagnosis. They include CSF changes with decreased Aβ and increased total- and phospho-tau levels, as well as increased brain retention of amyloid radioligand observed with PET. Total-tau level reflects the intensity of neural degeneration in the brain; phospho-tau levels the tangle pathology; and Aβ1–42 levels the amyloid burden [28].

Topographical markers evaluate less specific and downstream brain changes that result from AD pathology. They assess changes over time and are therefore markers of progression more targeted at assessing changes over time and predicting outcomes. They include medial temporal lobe atrophy, particularly of the hippocampus [29] and reduced glucose metabolism in temporo-parietal regions on FDG PET [30].

Mild cognitive impairment

This diagnostic label is applied if there is no disease to which MCI can be attributed. It remains a term of exclusion for individuals who do not meet the proposed new criteria for AD, in that they deviate from the clinicobiological phenotype of prodromal AD because they have memory symptoms that are not characteristic of AD or because they are biomarker negative.

UPDATING OF THE NEW CRITERIA

A new position paper was published some years after to improve the diagnostic framework [31]. Several refinements were proposed that have been made possible because rapid progress in the field in the past 4 years has improved our characterization of clinical phenotypes and the expression of disease captured by in vivo biomarkers of AD pathology. We propose that pathophysiological biomarkers indicating the specific presence of tau pathology (CSF or PET tau) and amyloid pathology (CSF or PET amyloid) have the necessary specificity for a diagnosis of AD at any point on the disease continuum. Downstream topographical markers of brain regional structural and metabolic changes have insufficient pathological specificity and are therefore now removed from the IWG diagnostic algorithm. Emphasis was also made on atypical forms of AD, which represent an estimated 6–14% of cases [32]. Each of these atypical forms of AD presents with a relative preservation of memory plus a recognizable (or characteristic) phenotype that might be accompanied by topographical evidence of brain damage (regional atrophy or hypometabolism) in related regions. It is now possible
to propose more precise definitions for atypical AD presentations, including a posterior variant of AD, a logopenic variant of AD, and a frontal variant of AD.

On the basis of these refinements, the diagnosis of AD can be simplified, requiring the presence of an appropriate clinical AD phenotype (typical or atypical) and a pathophysiological biomarker consistent with the presence of AD pathology (IWG-2 criteria, see Table 3). Thanks to the pathophysiological biomarkers, the criteria may apply for any stage of the disease (preclinical, prodromal, and dementia stages) considering the principle according to which: “One disease, one set of criteria”. We propose that downstream topographical biomarkers of the disease, such as volumetric MRI and fluorodeoxyglucose PET, might better serve in the measurement and monitoring of the course of disease. This paper also elaborates on the specific diagnostic criteria for atypical forms of AD, for mixed AD, and for the preclinical states of AD.

DEFINING THE PRECLINICAL STATE OF AD

During the past decade, the conceptual shift occurred in the field of AD considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. However, very little evidence is established on this “silent” stage of the disease and its definition varies from one study to the next [33]. A clarification was needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detected the disease at this asymptomatic stage. For these reasons, a consensus paper was published, addressing all these issues by providing evidence and practical recommendation [34]. For instance, a relationship between asymptomatic at risk and preclinical AD is only a matter of level of risk. Based on this high/low risk dichotomy, “preclinical AD” should be considered when the risk for a further progression to a clinical AD is particularly high (e.g., both Aβ and tau markers beyond pathological thresholds) and “asymptomatic at risk for AD” should be considered when the evolution to a clinical AD is less slightly or still needs to be determined (when the biomarkers pattern is insufficient with only one pathophysiological marker being abnormal) (see Table 4 and Fig. 1). The risk of progression to a clinical AD is the expression of a complex algorithm where the presence of AD brain lesions plays a key role and additional positive and/or negative factors need to be considered. If the sequential appearance of existing biomarkers and the polygenic and environmental protective/risk factors is considered, it should be possible, at some points, to predict the risk spectrum of a given individual and the putative time to the onset of a clinical disease, that is, to determine his conditions along a risk spectrum, ranging from negligible risk to immediate risk. Today, several genetic and lifestyle factors have been identified that may delay the onset of a clinical AD. After identifying subjects at risk for AD, based on the presence of specific biological predictors, the main issue will be to detect those with the highest likelihood to progress to definite clinical AD in the forthcoming months to years. The identification of markers, able to detect disease progression in a relative short time frame, before the onset of clinical symptoms becomes of crucial importance. To date, evidence from studies on blood-based biomarkers indicates a limited value for the characterization of preclinical stage of AD. Therefore, in the absence of definitive answers concerning the algorithm of progression to a clinical disease, we have considered that the knowledge of biomarkers status should not be disclosed at a preclinical stage.

Table 3
Added-value of the IWG-2 criteria

- Focus on the entire continuum of AD including the preclinical states
- Utilize a single diagnostic framework for the entire range of clinical severity
- Integrate pathophysiological biomarkers into all phases of the diagnostic approach to improve on the diagnostic specificity
- AD diagnosis based at least on the presence of brain amyloidosis
- Integrate causative mutations into diagnosis
- Simple to apply
- Can be used for inclusion of patients with “early AD”, an important target for clinical trials
Alzheimer’s disease
- Defined by both amyloidopathy and tauopathy (A+ and T+)
- Encompasses different stages in continuum
  - Preclinical AD
  - Clinical AD (prodromal; mild to severe dementia)
Asymptomatic at Risk for AD
- Cognitively normal individuals
- Biomarker pattern insufficient to reach above definition of AD
- Characterized as:
  - Asymptomatic Amyloid +
  - Asymptomatic Tau +

To conclude, it is noteworthy that significant progress was made in the diagnostic accuracy of AD during these last years. However, it is unfortunate that this is not yet translated into new perspectives for both symptomatic and disease modifying therapies.

DISCLOSURE STATEMENT

The author’s disclosure is available online (http://j-alz.com/manuscript-disclosures/17-0536r1).

REFERENCES

[1] McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. *Neurology* **34**, 939-944.
[2] Pillon B, Deweer B, Michon A, Malapani C, Agid Y, Dubois B (1994) Are explicit memory disorders of progressive supranuclear palsy related to damage to striatofrontal circuits? Comparison with Alzheimer’s, Parkinson’s, and Huntington’s diseases. *Neurology* **44**, 1264-1270.
[3] Dubois B, Andrade K, Levy R (2008) Executive dysfunction and neuropsychological testing. *Handb Clin Neurol* **89**, 35-52.
[4] Pillon B, Deweer B, Agid Y, Dubois B (1993) Explicit memory in Alzheimer’s, Huntington’s, and Parkinson’s diseases. *Arch Neurol* **50**, 374-379.
[5] Grober E, Buschke H, Crystal H, Bang S, Dresner R (1988) Screening for dementia by memory testing. *Neurology* **38**, 900-903.
[6] Deweer B, Lehericy S, Pillon B, Baulac M, Chiras J, Marsault C, Agid Y, Dubois B (1995) Memory disorders in probable Alzheimer’s disease: The role of hippocampal atrophy as shown with MRI. *J Neurourol Neuropsych Psychiatry* **58**, 590-597.
[7] Tounsi H, Deweer B, Ergis AM, Van der Linden M, Pillon B, Michon A, Dubois B (1999) Sensitivity to semantic cuing: An index of episodic memory dysfunction in early Alzheimer disease. *Alzheimer Dis Assoc Disord* **13**, 38-46.
[8] Dubois B, Albert ML (2004) Amnestic MCI or prodromal Alzheimer’s disease? *Lancet Neurol* **3**, 246-248.
[9] Mesulam MM (1987) Primary progressive aphasia–differential diagnosis from Alzheimer’s disease. *Ann Neurol* **22**, 533-534.
[10] Hodges JR, Patterson K, Oxbury S, Funnell E (1992) Semantic dementia: Progressive fluent aphasia with temporal lobe atrophy. *Brain* **115**(Pt 6), 1783-1806.
[11] Gibb WR, Luthert PJ, Marsden CD (1989) Corticobasal degeneration. *Brain* **112**(Pt 5), 1171-1192.
[12] Benson DF, Davis RJ, Snyder BD (1988) Posterior cortical atrophy. *Arch Neurol* **45**, 789-793.
[13] McKeith IG, Galasko D, Wilcock GK, Byrne EJ (1995) Lewy body dementia–diagnosis and treatment. *Br J Psychiatry* **167**, 709-717.
[14] Delacourte A, David JP, Sergeant N, Bué L, Wattez A, Vermersch P, Ghzouali F, Fallet-Bianco C, Pasquier F, Lébert F, Petit H, Di Menza C (1999) The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease. *Neurology* **52**, 1158-1165.
[15] Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol* **82**, 239-259.
[16] Sarazin M, Berr C, De Rotrou J, Fabrigoule C, Pasquier F, Légrain S, Michel B, Puel M, Volteau J, Touchon J, Verny M, Dubois B (2007) Amnestic syndrome of the medial temporal type identifies prodromal AD: A longitudinal study. *Neurology* **69**, 1859-1867.
[17] Sarazin M, Chauvire V, Gerardin E, Colliot O, Kinkingnéhun S, de Souza LC, Hugonot-Diener L, Garnero L, Lehericy S, Chupin M, Dubois B (2010) The amnestic syndrome of hippocampal type in Alzheimer’s disease: An MRI study. *J Alzheimers Dis* **22**, 285-294.
[18] Rami L, Sole-Padulles C, Fortea J, Bosch B, Lladó A, Antonell A, Olives J, Castellví M, Bartzes-Faz D, Sánchez-Valle R, Molinuevo JL (2012) Applying the new research diagnostic criteria: MRI findings and neuropsychological correlations of prodromal AD. *Int J Geriatr Psychiatry* **27**, 127-134.
[19] Wagner M, Wolf S, Reischies FM, Daerr M, Wolfsgäuer S, Jessen F, Popj J, Maier W, Hüll M, Frölich L, Hampel H, Perneckzy R, Peters O, Jahn H, Luckhaus C, Gertz HJ, Schröder J, Pantel J, Leuwacz P, Kornhuber J, Wiltfang J (2012) Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. *Neurology* **78**, 379-386.
[20] Derby CA, Burns LC, Wang C, Katz MJ, Zimmerman ME, L’italien G, Guo Z, Berman RM, Lipton RB (2013) Screening for predementia AD: Time-dependent operating characteristics of episodic memory tests. *Neurology* **80**, 1307-1314.
[21] Dubois B (2000) ‘Prodromal Alzheimer’s disease’: A more useful concept than mild cognitive impairment? *Curr Opin Neurol* **13**, 367-369.

[22] Lehericy S, Baulac M, Chiras J, Pierot L, Martin N, Pillon B, Deweer B, Dubois B, Marsault C (1994) Amygdalohippocampal MR volume measurements in the early stages of Alzheimer disease. *Am J Neuroradiol* **15**, 929-937.

[23] Silverman DH, Gambhir SS, Huang HW, Schwimmer J, Kim S, Small GW, Chodosh J, Czernin J, Phelps ME (2002) Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: A comparison of predicted costs and benefits. *J Nucl Med* **43**, 253-266.

[24] Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: A follow-up study. *Lancet Neurol* **5**, 228-234.

[25] Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén D, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Mathis CA, Längström B (2004) Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. *Ann Neurol* **55**, 306-319.

[26] Dubois B, Feldman H, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O’Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Revising the NINCDS-ADRDA criteria for the diagnosis of Alzheimer’s disease: Revising the NINCDS-ADRDA criteria. *Lancet Neurol* **6**, 734-746.

[27] Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampsel H, Jicha GA, Meguro K, O’Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ (2010) Revising the definition of Alzheimer’s disease: A new lexicon. *Lancet Neurol* **9**, 1118-1127.

[28] Blennow K, Hampel H, Weinr M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. *Nat Rev Neurol* **6**, 131-144.

[29] Sabuncu MR, Desikan RS, Sepulcre J, Yeo BT, Liu H, Schmansky NJ, Reuter M, Weiner MW, Buckner RL, Sperling RA, Fischl B, Alzheimer’s Disease Neuroimaging Initiative (2011) The dynamics of cortical and hippocampal atrophy in Alzheimer disease. *Alzheimer’s Disease Neuroimaging Initiative. Arch Neurol* **68**, 1040-1048.

[30] Mosconi L (2005) Brain glucose metabolism in the early and specific diagnosis of Alzheimer’s disease. FDG-PET studies in MCI and AD. *Eur J Nucl Med Mol Imaging* **32**, 486-510.

[31] Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateaman R, Cappa S, Cruch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, Rainovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL (2014) Advancing research diagnostic criteria for Alzheimer’s disease: The IWG-2 criteria. *Lancet Neurol* **13**, 614-629.

[32] Galton CJ, Patterson K, Xuereb JH, Hodges JR (2000) Atypical and typical presentations of Alzheimer’s disease: A clinical, neuropsychological, neuroimaging and pathological study of 13 cases. *Brain* **123**, 484-498.

[33] Epelbaum S, Genton R, Cavedo E, Habert MO, Lamari F, Gagliardi G, Lista S, Teichmann M, Bakardjian H, Hampel H, Dubois B (2017) Preclinical Alzheimer’s disease: A systematic review of the cohorts underlying the concept. *Alzheimers Dement* **13**, 454-467.

[34] Dubois B, Hampel H, Feldman H, Scheltens P, Aisen P, Andrieu S, Bakardjian H, Benali H, Bertram L, Blennow K, Broich K, Cavedo E, Cruch S, Dartigues JF, Duyckaerts C, Epelbaum S, Frisoni GB, Gauthier S, Genton R, Gouw AA, Habert MO, Holtzman DM, Kivipelto M, Lista S, Molinuevo JL, O’Bryant SE, Rabinovici GD, Rowe C, Salloway S, Schneider LS, Sperling R, Teichmann M, Carrillo MC, Cummings J, Jack CR Jr, Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer’s Association on “The Preclinical State of AD”, July 23, 2015, Washington DC, USA (2016) Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria. *Alzheimers Dement* **12**, 292-323.